Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria
Introduction: Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal he
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria
Introduction: Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal he
Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators
Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria: (pa
Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape
Paroxysmal nocturnal hemoglobinuria Paroxysmal nocturnal hemoglobinuria: (pa
ASH 2024 Update: Aplastic Anemia and PNH
Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Aplastic Anemia
Presenter(s)
Taha Bat, MD
In this webinar, Dr. Taha Bat discusses research most relevant to patients reported over the past year on the biology and treatment on Aplastic Anemia and PNH. These studies were presented at the American Society of Hematology (ASH) 2024 meeting and their findings will be…
Bharadhwaj Kolipakkam, MD
Institution
VCU Health
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Michael Jaglal, MD
Institution
Moffitt Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Health Professionals as Patients with Aplastic Anemia, MDS, PNH -2026 June
AAMDSIF is pleased to announce that we will host a support group exclusively for Health Care Professionals diagnosed with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_